Literature DB >> 2784659

Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.

J A Charlesworth1, P W Peake, J Golding, J D Mackie, B A Pussell, V Timmermans, D Wakefield.   

Abstract

The metabolism of the complement proteins C3 and C4 was studied in patients with active and inactive systemic lupus erythematosus (SLE) using highly purified, functionally active preparations. Nine patients with active and eight with inactive SLE were examined and 11 control subjects. There was a significant difference in the level of double stranded DNA antibodies, immune complexes, and serum C4 between the patients with active and inactive disease. Seven of 16 patients had detectable C4 null alleles and four had low serum concentrations of complement inhibitors. Each subject received approximately 370 kBq [125I]C4 and 93 kBq [131I]C3. Both patient groups showed significant C4 hypercatabolism compared with control subjects, but there was no difference between patients with active and inactive disease. The fractional catabolic rate (FCR) of C4 was comparable in subjects with and without detectable C4 null alleles. C4 production rate was significantly lower in patients with active SLE than in control subjects. There was significant C3 hypercatabolism for both patient groups, but C3 production was normal. An inverse correlation was observed between serum concentration and FCR. There was a highly significant correlation between C4 FCR and C3 FCR for control subjects + patients with inactive disease but not for those with active SLE combined with either controls or the inactive group. We conclude that complement hypercatabolism occurs in SLE irrespective of disease activity and that accelerated turnover does not account completely for the low C4 concentration observed in patients with active disease. This low concentration also results from impaired plasma production, which could reflect a high incidence of C4 null alleles or (inhibitory) factors associated with pathological complement activation, or both. Low C4 production could affect generation of the C3 converting enzyme C4b, 2b and thus influence proceeding complement activation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784659      PMCID: PMC1003704          DOI: 10.1136/ard.48.2.153

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Treatment of inflamed pulp in deciduous teeth. Histological study in dog.

Authors:  M de C Russo; T Okamoto; R Holland
Journal:  Bull Tokyo Dent Coll       Date:  1972-02

4.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

Review 5.  Inherited complement deficiency states and SLE.

Authors:  R I Rynes
Journal:  Clin Rheum Dis       Date:  1982-04

6.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

7.  Purification and structural analysis of the fourth component of human complement.

Authors:  C Bolotin; S Morris; B Tack; J Prahl
Journal:  Biochemistry       Date:  1977-05-03       Impact factor: 3.162

8.  Effects of anesthesia, surgery and inflammation upon host defense mechanisms. I. Effects upon the complement system.

Authors:  M Schutte; R DiCamelli; P Murphy; M Sadove; H Gewurz
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

9.  The complement system in type 1 (insulin-dependent) diabetes.

Authors:  J A Charlesworth; V Timmermans; J Golding; L V Campbell; P W Peake; B A Pussell; D Wakefield; N Howard
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

10.  Metabolism of C4 and factor B in rheumatoid arthritis. Relation to rheumatoid factor.

Authors:  R A Kaplan; J G Curd; D H Deheer; D A Carson; M K Pangburn; H J Müller-Eberhard; J H Vaughan
Journal:  Arthritis Rheum       Date:  1980-08
View more
  4 in total

1.  Distribution of the HindIII restriction fragment length polymorphism among patients with systemic lupus erythematosus with different concentrations of CR1.

Authors:  H Satoh; E Yokota; K Tokiyama; T Kawaguchi; Y Niho
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

2.  Increased production of the third component of complement (C3) by monocytes from patients with systemic lupus erythematosus.

Authors:  H Tsukamoto; A Ueda; K Nagasawa; Y Tada; Y Niho
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

3.  Complement inhibition by human vitronectin involves non-heparin binding domains.

Authors:  M Sheehan; C A Morris; B A Pussell; J A Charlesworth
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

4.  The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus.

Authors:  Anne Troldborg; Lisbeth Jensen; Bent Deleuran; Kristian Stengaard-Pedersen; Steffen Thiel; Jens Christian Jensenius
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.